Corrective Actions "Inadequate," FDA Warns Ranbaxy
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. regulators threaten seizure and injunction at Ohm Labs' Gloversville, N.Y., facility.
You may also be interested in...
The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics
Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.
The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics
Call it the Duragesic-ization or the Prevacid-ization, but not the Zocor-ization, of Lipitor.
Lipitor Patent Battle: Pfizer Plots New Course In Suit With Apotex
Two years ago, Pfizer inked a settlement with Ranbaxy, the first ANDA filer for generic Lipitor, that it believed would prevent generic competition in the U.S. until November 2011